Pharmaron Beijing Co., Ltd. (3759.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In HKD
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
25088
First IPO Date
November 28, 2019
| Name | Title | Pay | Year Born |
| Boliang Lou | Chairman & Chief Executive Officer | 2.34M | 1963 |
| Bei Zheng | Executive Vice President & Executive Director | 1.7M | 1967 |
| Xiaoqiang Lou | Co-Founder, President, Chief Operating Officer & Executive Director | 2.02M | 1968 |
| Mandy Xu | Senior Vice President of DMPK | 0 | N/A |
| Connie Sun | Senior Vice President & Global Head of Business Development of Small Molecules | 0 | N/A |
| Jingqi Huang | Senior Vice President of In Vivo Pharmacology | 0 | N/A |
| Shing Chung Li | CFO, Secretary of the Board, Accounting Supervisor & Employee Representative Director | 0 | 1978 |
| Celina Zhong | Senior Vice President of Human Resources | 0 | N/A |
| Katherine Lee | Chief Business Officer | 0 | N/A |
| Hua Yang | Chief Scientific Officer & Deputy Manager | 0 | 1962 |
| Stephen Lewinton | Senior Vice President of UK Operations | 0 | N/A |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.